OTCPK:BNKL

Stock Analysis Report

Executive Summary

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products.


Snowflake Analysis

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has Bionik Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BNKL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

87.0%

BNKL

13.1%

US Medical Equipment

9.9%

US Market


1 Year Return

-49.4%

BNKL

-8.0%

US Medical Equipment

-11.9%

US Market

Return vs Industry: BNKL underperformed the US Medical Equipment industry which returned -7.7% over the past year.

Return vs Market: BNKL underperformed the US Market which returned -11.5% over the past year.


Shareholder returns

BNKLIndustryMarket
7 Day87.0%13.1%9.9%
30 Day7.5%-10.9%-15.0%
90 Day102.8%-18.0%-21.5%
1 Year-49.4%-49.4%-7.3%-8.0%-10.0%-11.9%
3 Year-96.5%-96.5%41.4%37.5%12.3%5.1%
5 Year-99.4%-99.4%73.1%55.3%32.5%18.1%

Price Volatility Vs. Market

How volatile is Bionik Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bionik Laboratories undervalued compared to its fair value and its price relative to the market?

0.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BNKL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BNKL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BNKL is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: BNKL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNKL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BNKL is good value based on its PB Ratio (0.4x) compared to the US Medical Equipment industry average (3x).


Next Steps

Future Growth

How is Bionik Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bionik Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BNKL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bionik Laboratories's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Bionik Laboratories performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BNKL is currently unprofitable.

Growing Profit Margin: BNKL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNKL is unprofitable, and losses have increased over the past 5 years at a rate of -16.5% per year.

Accelerating Growth: Unable to compare BNKL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNKL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).


Return on Equity

High ROE: BNKL has a negative Return on Equity (-40.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is Bionik Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: BNKL's short term assets ($5.4M) exceed its short term liabilities ($2.7M).

Long Term Liabilities: BNKL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: BNKL's debt to equity ratio (0.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BNKL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: BNKL has a low level of unsold assets or inventory.

Debt Coverage by Assets: BNKL's debt is covered by short term assets (assets are 74.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNKL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BNKL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24% each year


Next Steps

Dividend

What is Bionik Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNKL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BNKL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNKL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNKL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BNKL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Eric Dusseux (51yo)

2.5s

Tenure

US$1,031,769

Compensation

Dr. Eric Michel Dusseux, MD, MSc, MBA, has been Director of MC10, Inc. since June 2019. Dr Dusseux has been the Chief Executive Officer at Bionik Laboratories Corp. since September 1, 2017. Dr. Dusseux was ...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD1.03M) is above average for companies of similar size in the US market ($USD601.33K).

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Eric Dusseux
CEO & Director2.5yrsUS$1.03mno data
Michal Prywata
Co-Founder1yrUS$233.44k1.95% $214.9k
Leslie Markow
Chief Financial Officer5.5yrsUS$252.47kno data
William Harris
Marketing Director3yrsno datano data
Loren Wass
Chief Commercial Officer0.50yrno datano data

2.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: BNKL's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Dusseux
CEO & Director2.5yrsUS$1.03mno data
Michal Prywata
Co-Founder1yrUS$233.44k1.95% $214.9k
Joseph Martin
Independent Director2yrsUS$50.00kno data
Gary Henley
no datano datano data
André-Jacques Auberton-Hervé
Chairman of the Board2.17yrsUS$180.00kno data
Peter Malone
Independent Director2yrsUS$50.00kno data
Remi Gaston-Dreyfus
Independent Director2.5yrsUS$50.00kno data
Charles Matine
Independent Director1.5yrsUS$32.53kno data
Audrey Thevenon
Independent Director1.5yrsUS$32.53kno data

2.0yrs

Average Tenure

60yo

Average Age

Experienced Board: BNKL's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 105.6%.


Top Shareholders

Company Information

Bionik Laboratories Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bionik Laboratories Corp.
  • Ticker: BNKL
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$11.030m
  • Shares outstanding: 5.13m
  • Website: https://www.bioniklabs.com

Number of Employees


Location

  • Bionik Laboratories Corp.
  • 483 Bay Street
  • Office N105
  • Toronto
  • Ontario
  • M5G 2C9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BNKLOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2015

Biography

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company is also developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; and ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, strokes, and other mobility disabilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 01:08
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.